Mannkind, Game-Chancer in Sachen Diabetik? (Seite 405)
eröffnet am 11.01.11 13:02:26 von
neuester Beitrag 03.04.24 20:06:55 von
neuester Beitrag 03.04.24 20:06:55 von
Beiträge: 6.825
ID: 1.162.683
ID: 1.162.683
Aufrufe heute: 1
Gesamt: 593.804
Gesamt: 593.804
Aktive User: 0
ISIN: US56400P7069 · WKN: A2DMZL · Symbol: MNKD
4,1550
USD
-0,84 %
-0,0350 USD
Letzter Kurs 15:47:47 Nasdaq
Neuigkeiten
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,9000 | +59,66 | |
| 2,2999 | +25,68 | |
| 1,9200 | +23,87 | |
| 6,9300 | +17,46 | |
| 0,6185 | +14,54 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 3,4000 | -11,69 | |
| 3,7200 | -12,88 | |
| 3,2100 | -15,47 | |
| 0,5050 | -15,83 | |
| 1,9500 | -25,14 |
Beitrag zu dieser Diskussion schreiben
Feedback
Kauft statt kaut!
Antwort auf Beitrag Nr.: 50.769.531 von Gangal am 04.10.15 09:11:27Oder wie seht Ihr denn das?
Übergabe der klinischen Studie an Health Authority Germany: Ethics Commission
Übergabe der klinischen Studie an Health Authority Germany: Ethics Commission
Tolle Seite, müßte doch mit dem Teuel zugehen wenn sich solch eine revolutionäre einfache und schmerzfreie Therpie nicht durchsetzen würde!
Trading Spotlight
Wäre schön wenn es so kommt...
I spoke to 1 endo(sorry no name/privacy issues)told me that Afrezza is incredible in lowering A1C levels and it will be a blockbuster
Aus dem Yahoo Board (kann ich keinen Link schicken)
I spoke to 1 endo(sorry no name/privacy issues)told me that Afrezza is incredible in lowering A1C levels and it will be a blockbuster
Aus dem Yahoo Board (kann ich keinen Link schicken)
Interessant... Kommt es bald zur Zulassung in Deutschland bzw. Europa???
On the clamp study that was just completed, look at the health authorities reviewing:Germany & USA!!!
https://clinicaltrials.gov/archive/NCT02470637/2015_09_29
On the clamp study that was just completed, look at the health authorities reviewing:Germany & USA!!!
https://clinicaltrials.gov/archive/NCT02470637/2015_09_29
Quelle investor village von techstockguru gepostet heute
The explanation is really easy and its 100% factual. SNY has said all along that they would go thru a process of education, target certain endos and early adopters, work thru insurance approvals, start print ads, seek better labeling thru further trials and then roll out on a large scale. We are just starting the 2nd half of the game and are right on track for a victory. Scrip counts will eventually hockey stick once all the steps are in place and execution has been given enough time.
DYOR.LINK NICHT POSTBAR
The explanation is really easy and its 100% factual. SNY has said all along that they would go thru a process of education, target certain endos and early adopters, work thru insurance approvals, start print ads, seek better labeling thru further trials and then roll out on a large scale. We are just starting the 2nd half of the game and are right on track for a victory. Scrip counts will eventually hockey stick once all the steps are in place and execution has been given enough time.
DYOR.LINK NICHT POSTBAR
bleibt schwach. Langsam glaube ich auch, dass der "soft-launch" eher dazu dient die massiven Probleme zu vertuschen.
Naja, noch halte ich meine shares und hoffe ...
Naja, noch halte ich meine shares und hoffe ...
Durchsuchen
Mannkind, Game-Chancer in Sachen Diabetik?
